ESTRO 2020 Abstract Book

S601 ESTRO 2020

Results Forty eight patients (mean age 56.25 years, 13 male) with mean dose (74 Gy) were included. T1 ratio, T2 M-S ratio, T2 M-M , T2 M-CSF and apparent diffusion coefficient (ADC) ratio correlated with HPE as follows (p = 0.02, 0.823, 0.332, 0.412, 0.709 respectively). HPE correlation with TLC had a p value of 0.823. Conclusion Quantitative MRI characteristic like T1 ratio is potential marker of the histopathological inflammation in RIC. PO-1141 Prognostic factors in gynaecological cancer patients treated with radiotherapy for brain metastases E. Nakken 1 , S.S. Os 1 , K. Skipar 1 , K. Bruheim 1 1 Oslo University Hospital, Radiumhospitalet, Oslo, Norway Purpose or Objective Brain metastases (BM) from gynaecological cancers are rare and carry a poor prognosis. No common treatment guidelines exist for this patient group due to lack of data. For clinicians, life prognostication and treatment decision is a difficult task in this situation. Information that can shed light over this issue is therefore much needed. Material and Methods A retrospective analysis of patients with BM from a gynaecological cancer treated at the Norwegian Radium Hospital, Oslo University Hospital was performed. All patients receiving radiotherapy due to BM from 2006-2017 were identified from the hospitals radiotherapy registry. Medical data were found in the hospital’s medical records. Both patients treated with stereotactic brain radiotherapy (SBRT) and whole brain radiotherapy (WBRT) were included. Results 117 patients were eligible for analysis. Mean age at diagnosis of BM was 63 years (range 24-91). Mean time from primary diagnosis to diagnosis of BM was 48 months. 36 patients (31 %) had a single metastasis, 30 % had 2-4 metastases and the remaining 39 % was diagnosed with more than 4 metastases. 67 % of the patients received WBRT only, 14 % received SBRT while the rest (20 %) had a combination of WBRT and SBRT. Surgery was performed in addition to radiotherapy in 13 % of the patients. Median overall survival (OS) from diagnosis of brain metastases to death was 5.2 months (range 0.03 – 136.1). 29 patients (25 %) were still alive 12 months after treatment. The majority of patients had a primary diagnosis of ovarian cancer (44%). Endometrial, cervical and vulvar cancer accounted for 33 %, 21 % and 3 % respectively. 18 patients (15%) did not show any sign of extracranial disease. 43 patients (37 %) had an ECOG score of 3-4 at the time of diagnosis of BM. Absence of extracranial disease and low ECOG status (0-2) was significantly associated with longer survival (figure 1 and 2). Neither primary gynaecological cancer diagnosis, age at diagnosis of BM, time from primary diagnosis to BM diagnosis or number of BM was associated with survival. For patients surviving more than 12 months only absence of extracranial disease showed a significant correlation. 22 % of the patients received radiotherapy within the last 30 days of their life

Conclusion Gynaecological cancer patients who present with brain metastases without extracranial disease and good performance status show a favourable prognosis. This information is important for the physician both in treatment decision and when giving information to the patient about their prognosis. A proportion of these patients should probably receive best supportive care and no radiotherapy for their brain metastases. For the majority of patients with gynaecological cancers and BM the prognosis remains poor. PO-1142 Lymphadenectomy for vaginal melanoma, does it improve outcomes? Z. Horne 1 , S. Teterichko 2 , R. Wegner 1 , S. Hasan 3 , S. Crafton 4 , E. Miller 4 , T. Krivak 4 , P. Sukumvanich 2 , S. Beriwal 5 1 Allegheny Health Network Cancer Institute, Radiation Oncology, Pittsburgh, USA ; 2 University of Pittsburgh Medical Center, Gynecologic Oncology, Pittsburgh, USA ; 3 New York Proton Center, Radiation Oncology, New York, USA ; 4 Allegheny Health Network Cancer Institute, Gynecologic Oncology, Pittsburgh, USA ; 5 University of Pittsburgh Medical Center, Radiation Oncology, Pittsburgh, USA Purpose or Objective Vaginal melanomas are rare with case reports/series to guide treatment protocols. Most treatment is guided by mucosal melanomas of the head and neck. Systematic lymphadenectomy has been suggested to be of benefit in vulvar melanomas but its value is unclear in vaginal melanomas. Material and Methods The National Cancer Database was queried for women diagnosed with non-metastatic melanoma of the vagina